DNTH

Dianthus Therapeutics, Inc. (DNTH) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune diseases. The company operates as a single segment and is currently advancing two primary product candidates: claseprubart (a C1s inhibitor) and DNTH212 (a bifunctional BDCA2 and BAFF/APRIL inhibitor). The company is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Note: Cash, Cash Equivalents & Investments includes $627.7M in cash/cash equivalents and $597.5M in marketable securities as of March 31, 2026.

Material Changes vs. Prior Period

• Capital Raise: The most significant change was a public offering in March 2026, raising approximately $719.0 million in gross proceeds. Combined with an ATM offering ($58.7M net proceeds), financing activities provided $739.4 million in cash, drastically improving liquidity compared to Q1 2025.
• Revenue Decline: License revenue decreased to $0.5 million from $1.2 million year-over-year due to a decrease in reimbursable costs associated with ongoing clinical trials under the Tenacia License Agreement.
• Expense Growth: Total operating expenses increased by $12.7 million (37%) to $47.0 million.
  • R&D Expenses: Increased $7.5 million to $34.5 million, driven by higher external clinical operations costs for claseprubart (Phase 2/3 trials) and internal personnel/stock-based compensation increases.
  • G&A Expenses: Increased $5.2 million to $12.5 million, primarily due to higher stock-based compensation ($2.9M increase) and personnel costs.
• Investment Income: Interest and investment income rose to $6.3 million from $3.8 million, reflecting higher cash and investment balances.

Guidance, Outlook, and Risks

Outlook and Milestones:

• Claseprubart: Management expects to initiate a Phase 3 registrational trial in generalized Myasthenia Gravis (gMG) in mid-2026 with results expected in late 2028. In March 2026, the company announced an early "GO" decision in the Phase 3 CAPTIVATE trial for CIDP, reducing the required enrollment. Initial results for the Phase 2 MoMeNtum trial (MMN) are expected in Q4 2026.
• DNTH212: A Phase 1 study in China was initiated in December 2025, with healthy volunteer results expected in H2 2026.
• Liquidity: Management believes existing cash and investments ($1.2 billion) are sufficient to fund operations into 2030.

• Development Risk: As a clinical-stage company, Dianthus has no product revenue and relies on successful clinical outcomes and regulatory approvals.
• Capital Requirements: While currently well-capitalized, the company expects R&D and G&A costs to increase significantly. Future capital needs may require additional equity or debt financing, potentially causing dilution.
• License Agreements: The company has significant contingent milestone obligations, including up to $962 million in potential payments to Nanjing Leads Biolabs for DNTH212 and up to $15 million to Tenacia for claseprubart.
• Macroeconomic Factors: Risks include inflation, interest rates, geopolitical instability, and supply chain disruptions.

Key Investor Verification Points

• Cash Runway: Verify the sustainability of the $1.2 billion cash position against the projected burn rate as Phase 3 trials for claseprubart scale up.
• Clinical Trial Enrollment: Monitor the actual enrollment rates and interim data for the CAPTIVATE (CIDP) and MoMeNtum (MMN) trials, as these drive the timeline for potential BLA filings.
• License Revenue Recognition: Review the specific cost-based input method used for recognizing revenue under the Tenacia agreement, as this impacts reported revenue volatility.
• Dilution Impact: Assess the impact of the recent $719M offering and outstanding pre-funded warrants (1.35M shares) on future earnings per share.
• DNTH212 Milestones: Track the initiation of the Dianthus-led Phase 1 study for DNTH212, which triggers an $8.0 million milestone payment to Nanjing Leads Biolabs.